Internal Medicine, Endocrinology, Diabetes, & Metabolism · Greenville, SC
NPI
1750321998
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
877 West Faris Road, Suite D
Greenville, SC, 29605
Phone (864) 455-9031
Groups this clinician bills Medicare through
Medicare paid, 2024
$86K
1,585 services
Medicare patients, 2024
544
Average age 73
Drug cost, 2024
$1.8M
3,085 prescriptions
Company payments, 2024
$125
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James K Horton was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 531 times for 341 patients. In total James K Horton billed 1,585 services in 14 codes, and Medicare paid $86K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-06-13.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 531 | 341 | $11.51 | $6,112 |
| 99214 Office E&M - Established | Office | 501 | 319 | $84.24 | $42K |
| 99213 Office E&M - Established | Office | 186 | 171 | $56.43 | $10K |
| 76536 Ultrasound - Nonspecific | Office | 169 | 169 | $68.36 | $12K |
| 99204 Office E&M - New | Office | 73 | 73 | $117.01 | $8,542 |
| 99203 Office E&M - New | Office | 41 | 41 | $72.70 | $2,981 |
| 95251 Test - Miscellaneous | Office | 29 | 16 | $25.22 | $731 |
| 83036 Blood Count | Office | 21 | 18 | $9.52 | $200 |
| 10005 Other Organ Systems | Office | 19 | 17 | $94.69 | $1,799 |
By year: 2022 $79K for 1,019 services; 2023 $74K for 979 services; 2024 $86K for 1,585 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 21 | 18 | $9.52 | $200 |
Medicare prescription drug claims, 2024
In 2024, the drug James K Horton prescribed most often to Medicare patients was Levothyroxine Sodium, with 904 prescriptions and refills. In total James K Horton wrote 3,085 Medicare prescriptions that cost $1.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 904 | 2,527 | 254 | $7,887 |
| Methimazole Generic | 436 | 1,205 | 124 | $4,065 |
| Synthroid Levothyroxine Sodium | 195 | 491 | 51 | $18K |
| Testosterone Cypionate Generic | 90 | 109 | 14 | $1,431 |
| Atorvastatin Calcium Generic | 61 | 182 | 22 | $685 |
| Hydrocortisone Generic | 60 | 134 | 20 | $4,057 |
| Ozempic Semaglutide | 58 | 78 | 14 | $71K |
| Novolog Flexpen Insulin Aspart | 51 | 87 | 18 | $16K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 51 | 115 | 15 | $11K |
| Calcitriol Generic | 45 | 107 | 13 | $2,094 |
| Farxiga Dapagliflozin Propanediol | 43 | 77 | Under 11 | $42K |
| Metformin Hcl Er Metformin Hcl | 40 | 120 | 14 | $506 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 37 | 103 | 16 | $4,864 |
| Cabergoline Generic | 35 | 65 | Under 11 | $1,929 |
| Amlodipine Besylate Generic | 34 | 102 | 14 | $166 |
Brand drugs: 1,166 claims; generic drugs: 1,835 claims.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid James K Horton $125 ($125 in general payments such as food, travel and fees) from 1 company. The largest payer was Insulet Corporation with $125.
| Company | Payments | Amount |
|---|---|---|
| Insulet Corporation PODD | 1 | $125 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.